University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, 11100 Euclid Ave, Cleveland, OH 44106, United States.
Bayer, 400 S Oak Way, Reading RG2 6AD, United Kingdom.
Maturitas. 2024 Oct;188:108071. doi: 10.1016/j.maturitas.2024.108071. Epub 2024 Jul 23.
Vasomotor symptoms induced by endocrine therapy are common in breast cancer survivors and a risk factor for therapy discontinuation and lower quality of life. The REALISE study evaluated the real-world treatment landscape in breast cancer survivors with vasomotor symptoms taking endocrine therapy, including pharmaceuticals, lifestyle changes, and over-the-counter products.
Secondary analysis of the Adelphi Vasomotor Disease Specific Programme™, a large cross-sectional point-in-time survey and chart review conducted in the US and five European countries (February-October 2020). Oncologists provided demographic, clinical, and treatment data for adult breast cancer survivors with induced vasomotor symptoms taking endocrine therapy (tamoxifen or aromatase inhibitors); patients voluntarily completed self-report surveys on their symptom severity, concomitant sleep and/or mood symptoms, lifestyle changes, and use of over-the-counter products.
Patient characteristics; vasomotor symptom severity; use of pharmaceuticals, lifestyle changes, and over-the-counter products (from pre-defined lists); lines of treatment.
Overall, 77 oncologists reported data for 618 breast cancer survivors, of whom 183 (29.6 %) completed self-report forms. Physicians classified 420 (68.0 %) women as experiencing moderate-severe vasomotor symptoms, of whom 66.9 % were receiving treatment. In total, 15.2 % of all breast cancer survivors were prescribed systemic hormone therapy. Venlafaxine (24.7 %), citalopram (16.5 %), and paroxetine (13.6 %) were the most commonly prescribed nonhormonal medications. Lifestyle changes (77.8 %) and over-the-counter products (61.6 %) were common, especially in patients with concomitant sleep and/or mood symptoms.
Despite contraindications, a relatively large proportion of treatment-seeking breast cancer survivors with vasomotor symptoms were prescribed systemic hormone therapy. This, combined with high patient-reported use of lifestyle changes and over-the-counter products, suggests a need for symptomatic relief and demand for new nonhormonal alternatives with established safety profiles in this population.
内分泌治疗引起的血管舒缩症状在乳腺癌幸存者中很常见，也是治疗中断和生活质量下降的风险因素。REALISE 研究评估了接受内分泌治疗（他莫昔芬或芳香化酶抑制剂）有血管舒缩症状的乳腺癌幸存者的真实世界治疗情况，包括药物、生活方式改变和非处方产品。
这是 Adelphi 血管舒缩疾病专项计划的二次分析，该计划是一项在美国和五个欧洲国家（2020 年 2 月至 10 月）进行的大型横断面时点调查和图表审查。肿瘤学家提供了接受内分泌治疗（他莫昔芬或芳香化酶抑制剂）有诱导性血管舒缩症状的成年乳腺癌幸存者的人口统计学、临床和治疗数据；患者自愿完成关于其症状严重程度、伴随的睡眠和/或情绪症状、生活方式改变和使用非处方产品的自我报告调查。
患者特征；血管舒缩症状严重程度；药物使用（来自预定义清单）、生活方式改变和非处方产品使用；治疗线数。
总体而言，77 名肿瘤学家报告了 618 名乳腺癌幸存者的数据，其中 183 名（29.6%）完成了自我报告表。医生将 420 名（68.0%）女性归类为患有中重度血管舒缩症状，其中 66.9%正在接受治疗。共有 15.2%的乳腺癌幸存者接受了全身激素治疗。文拉法辛（24.7%）、西酞普兰（16.5%）和帕罗西汀（13.6%）是最常开的非激素药物。生活方式改变（77.8%）和非处方产品（61.6%）很常见，尤其是在有睡眠和/或情绪症状的患者中。
尽管存在禁忌症，但相当大比例的有血管舒缩症状的治疗寻求乳腺癌幸存者被开了全身激素治疗。这与患者报告的生活方式改变和非处方产品的高使用率相结合，表明该人群需要缓解症状，并需要具有既定安全性的新的非激素替代药物。
